Zhejiang Medicine gets approval for Ringer's injection

Zhejiang Medicine Co., Ltd. (600216.SS) announced it has received approval from the National Medical Products Administration for its Compound Sodium Acetate Ringer's Injection (250ml). The injection, classified as a Category 3 chemical drug, is indicated for replenishing extracellular fluid in cases of reduced circulating blood volume and interstitial fluid, as well as correcting metabolic acidosis. The product, first launched in Japan in 2000 by Otsuka Pharmaceutical, saw approximately RMB 1.8 billion in sales in China in 2023. While several companies already produce this injection in China, Zhejiang Medicine's entry into the market is expected to enhance its competitive position. The company has invested approximately RMB 480,510 in research and development for this product to date. The company cautioned investors about potential uncertainties related to policy and market conditions.